Omeros(NASDAQ) OMER

Omeros Corporation creates medicines for patients with rare and complex diseases. It develops treatments that target the immune system and brain disorders. These products help people manage inflammatory conditions and addiction.

Focusing on Rare Disease Solutions

• Narsoplimab: Lead antibody candidate for treating blood-related complications following stem-cell transplants and chronic kidney disease.
• Complement System Inhibitors: Therapies designed to control the body’s natural defense system to treat rare immunological disorders.
• Addiction Program Assets: Small-molecule drugs targeting the brain to help people overcome opioid and nicotine dependence.
• CAR T-Cell Research: Development of modified immune cells to identify and destroy tumors in cancer patients.

Advancing Through Clinical Stages

• Completed pivotal trials for Narsoplimab in patients with stem-cell transplant-associated thrombotic microangiopathy.
• Progressed MASP-3 inhibitors into clinical testing for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
• Advanced early-stage studies for treatments targeting addiction, compulsive disorders, and movement issues.
• Initiated Phase II trials to evaluate lead assets for potential use in treating COVID-19.

Specializing in Complex Pathways

The company focuses on specific immune system pathways to address diseases with few available treatment options. Its research platform combines small-molecule drug discovery with protein-based therapies to target both physical and behavioral health conditions.

Key Metrics and Performance

• Market capitalization reached $686.0 million in Q2 2026, up 290.3% year over year.
• The price-to-earnings ratio was 13.2 in Q2 2026.
• The company supported research and operations with 175 full-time employees as of the profile date.

Bottom Line

Omeros has evolved from an early research firm into a late-stage developer of specialized treatments for rare diseases. Its strategy focuses on advancing a diverse pipeline of immune and central nervous system therapies.